Remove 2021 Remove Disease Remove Vaccine
article thumbnail

mRNA Tech Transfer Phase 2.0 Discussed at G20 Summit

The Pharma Data

This meant putting the fundamentals of mRNA production directly into the hands of local innovators — a dramatic departure from previous models that kept much of vaccine production within a small number of firms in high-income settings. mRNA Technology Transfer Programme Moves Into Phase 2.0, 2026–2030).

Vaccine 40
article thumbnail

Olgotrelvir 

New Drug Approvals

“Second Generation Oral Mpro Inhibitor for COVID-19 Treatment Proceeds in Phase 3 Study” Precision Vaccinations. Jump up to: a b “Coronavirus disease 2019 (COVID-19) emerging treatments” BMJ Best Practice US. Berdowska I, Matusiewicz M (October 2021). . ^ Jump up to: a b c d e f Hackett DW (26 June 2023).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vor, with new CEO, changes course to target autoimmune disease

BioPharma Drive: Drug Pricing

Published June 26, 2025 Gwendolyn Wu Senior reporter post share post print email license B cells, like those pictured above, malfunction in autoimmune disease. Progress developing a treatment for leukemia led the company in 2021 to price a $177 million initial public offering. But a rocky few years forced Vor to change direction.

Disease 109
article thumbnail

Levers for Biological Progress

Codon

Amodei also imagines the ways AI could accelerate biological research and yield miraculous cures in the 21st century; everything from the prevention and treatment of nearly all infectious and inherited diseases to the elimination of most cancers. This essay focuses on how we might do both, specifically for the cell. Subscribe to Asimov Press.

DNA 133
article thumbnail

Merck to buy Verona and its lung drug in $10B deal

BioPharma Drive: Drug Pricing

has agreed to pay $10 billion to buy London-based Verona Pharma, scooping up a potential multibillion-dollar new drug to treat chronic obstructive pulmonary disease in a deal announced Wednesday. In 2021, Merck agreed to pay $11.5 Alamy Merck & Co. billion for Acceleron Pharma.

article thumbnail

Organon drug for endometriosis falls short in mid-stage study

BioPharma Drive: Drug Pricing

Organon acquired the drug in its purchase of Forendo Pharma in 2021. Morgan Healthcare Conference in January. The company had hoped to kick off Phase 3 research in 2026 and launch the medicine around 2029.

article thumbnail

Seth Klarman selected Chair of the Broad Institute Board of Directors

Broad Institute

Klarman joined the Broad Institute Board of Directors when it was formed in 2009 and has worked closely with Schmidt and other fellow members to steward the institution in its mission of improving human health by advancing the understanding and treatment of disease.&

Science 110